AI-Driven Transfer Learning and Generative Model (TransGenGRU) Enables the Drug Discovery of Novel Natural Guaianolide Sesquiterpene Derivatives as Potent NLRP3 Inhibitors
Authors:
- 10 October 2025
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (20) , 21534-21559
Abstract
The NLRP3 inflammasome is recognized as a critical mediator of innate immunity, which can regulate the maturation of proinflammatory cytokines. Nowadays, several natural products have been confirmed to exhibit potent NLRP3 inhibitory effects and possess novel binding mechanisms with NLRP3. Herein, an AI-driven model (TransGenGRU) is proposed to generate novel natural products with NLRP3 inhibitory activities. Through the modeling of TransGenGRU, two guaianolide sesquiterpenoids (A3 and A8) are identified to possess moderate NLRP3 inhibitory activities. Then, through detailed structure optimization, E1 demonstrates the most potent NLRP3 inhibitory activity (IC50 = 24.42 nM), and the inhibitory effect on the NLRP3 inflammasome is correlated to the assembly of NLRP3/pro-caspase-1/ASC. Notably, E1 is confirmed to covalent-irreversibly interact with Cys280 that is totally different from MCC950. Besides, E1 also demonstrates potent anti-inflammatory activity in vivo, favorable DMPK profiles, and low hERG toxicity. Thus, E1 has been considered a novel and potent NLRP3 inhibitor.Keywords
Funding Information
- Graduate Research and Innovation Projects of Jiangsu Province (KYCX21_1720, KYCX21_1791, KYCX22_2001, SJCX23_0744)
- Nanjing University of Chinese Medicine (NZY81703342, ZYXJC2024-007)
- Natural Science Foundation of Jiangsu Province (BK20211301)
- National Natural Science Foundation of China (82073719, U2102201, U24A20785)
This publication has 63 references indexed in Scilit:
- Transfer learning empowers accurate pharmacokinetics prediction of small samplesDrug Discovery Today, 2024
- Product feature sentiment analysis based on GRU-CAP considering Chinese sarcasm recognitionExpert Systems with Applications, 2023
- Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseasesActa Pharmaceutica Sinica B, 2022
- A multichannel embedding and arithmetic optimized stacked Bi-GRU model with semantic attention to detect emotion over text dataApplied Intelligence, 2022
- The role of NLRP3 inflammasome in colorectal cancer: potential therapeutic targetClinical and Translational Oncology, 2022
- Synthesis and pharmacological validation of fluorescent diarylsulfonylurea analogues as NLRP3 inhibitors and imaging probesEuropean Journal of Medicinal Chemistry, 2022
- Application advances of deep learning methods for de novo drug design and molecular dynamics simulationWIREs Computational Molecular Science, 2021
- Computational Approaches for De Novo Drug Design: Past, Present, and Future2020
- Inflammasome Complexes: Emerging Mechanisms and Effector FunctionsCell, 2016
- Study on the pharmacokinetics and metabolism of costunolide and dehydrocostus lactone in rats by HPLC‐UV and UPLC‐Q‐TOF/MSBiomedical Chromatography, 2014